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Objectives This study sought to evaluate the relationship between subclinical hypothyroidism (SCH) and all-cause and
cardiovascular disease (CVD) mortality.
Background SCH may increase the risks of hypercholesterolemia and atherosclerosis. The associations between SCH and
all-cause or CVD mortality are uncertain, on the basis of the results of previous studies.
Methods A baseline cohort of 115,746 participants without a history of thyroid disease, 20 years of age, was recruited
in Taiwan. SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.0 to 19.96 mIU/l with nor-
mal total thyroxine concentrations. Euthyroidism was defined as a serum TSH level of 0.47 to 4.9 mIU/l. Cox
proportional hazards regression analysis was used to estimate the relative risks (RRs) of death from all-cause
and CVD for adults with SCH during a 10-year follow-up period.
Results There were 3,669 deaths during the follow-up period; 680 deaths were due to CVD. Compared with subjects with
euthyroidism, after adjustment for age, sex, body mass index, diabetes, hypertension, dyslipidemia, smoking,
alcohol consumption, betel nut chewing, physical activity, income, and education level, the RRs (95% confidence
interval) of deaths from all-cause and CVD among subjects with SCH were 1.30 (1.02 to 1.66), and 1.68 (1.02 to
2.76), respectively.
Conclusions Adult Taiwanese with SCH had an increased risk for all-cause mortality and CVD death. (J Am Coll Cardiol
2012;60:730–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.047Subclinical hypothyroidism (SCH) is defined as an elevated
thyroid-stimulating hormone (TSH) level with a normal
thyroxine (T4) level. The prevalence of SCH has been
reported to be between 4% and 20% (1–4). It varies in
populations as a function of sex, age, or ethnic group (1–4).
The proposed adverse consequences of SCH include sys-
temic hypothyroid symptoms, psychiatric symptoms, pro-
gression to overt hypothyroidism, and hypercholesterolemia
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2012, accepted March 19, 2012.(5,6). SCH may impair left ventricular diastolic function,
alter endothelial function, increase the C-reactive protein
level, and thus increase the risk of atherosclerosis (5). Being
associated with hypercholesterolemia and atherosclerosis,
screening and treatment for SCH has been suggested to
prevent cardiovascular disease (CVD) (7). In their review,
Surks et al. (8) concluded that supporting data concerning
the associations of SCH with adverse clinical outcomes or
benefits of treatment are few. CVD is the leading cause of
death in the United States and the second major cause of
death in Taiwan (9,10). The associations between SCH and
cardiovascular outcomes and/or mortality are uncertain
based on the existing literature (11–16). In this study, we
determined the impact of SCH on all-cause mortality and
cardiovascular death in a large Taiwanese cohort.
Methods
Subjects and measurements. The data were collected from
4 private nationwide MJ Health Screening Centers in
Taiwan from 1998 to 1999 as previous reports (17,18). The
registered health practitioners in these centers provide a
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August 21, 2012:730–7 Subclinical Hypothyroidism and Mortalitymultidisciplinary team approach of health assessment for
their members. Most of the members undergo health
examinations every 3 to 4 years, and approximately 30% of
the members will receive the same health check-up every
year. A total of 124,456 participants age 20 years and above
were recruited into this study. Nine hundred fifty-three
participants (0.8%) who had a history of thyroid disease
with medication treatment and 3,310 participants (2.6%)
with missing TSH or total T4 levels at entry were excluded.
SCH was defined as a serum TSH level of 5.0 to 19.96
mIU/l with normal total T4 concentrations (57.9 to 154.4
mol/l). Euthyroidism was defined as a serum TSH level of
.47 to 4.9 mIU/l (16). Therefore, participants with serum
SH levels 20 mIU/l or 0.47 mIU/l were also excluded
(n  4,447). Finally, 115,746 participants were included for
analysis in the study. The population structure (age and sex)
in our study was similar to national data of the adults
published by the Taiwanese government (19). Deaths were
ascertained by computer linkage to the national death
registry (death certificates created by the Department of
Health, Taiwan) using ID numbers. These death certificates
have been validated. The overall agreement rates between
the reviewer and coders were above 80% (20). All deaths
that occurred between study entry and December 2008 were
included. Deaths with the International Classification of
Disease, ninth revision (ICD-9) codes 390 to 459 were
classified as CVD-related deaths (21). We use all-cause
mortality as the primary outcome and CVD death as a
secondary outcome.
Anthropometric index and laboratory assays. The an-
thropometric characteristics, blood pressure (BP), plasma
glucose, total cholesterol (TCHOL), high-density lipopro-
tein cholesterol (HDL-C), and triglycerides were measured
and described as in a previous report (22). Thyroid function
(TSH and total T4) were also measured (Abbott AxSYM,
Abbott Park, Illinois). The coefficients of variation were
3.6% to 4.3% at level 2.837 to 3.419 mIU/l and 8.1% to
8.8% at level 15.32 to 19.727 mIU/l for the precision of
TSH assay, and were 2.8% to 3.6% at level 101.65 to 108.85
nmol/l for that of total T4. In brief, trained staff measured
height (to the nearest 0.1 cm) and weight (to the nearest 0.1
kg). Body mass index (BMI) was calculated as weight (kg)
divided by height squared (m2). The BP was measured in
he right arm using a standard mercury sphygmomanometer
ith an appropriately sized cuff while participants were in a
eated position. Blood was drawn with minimal trauma
rom an antecubital vein in the morning after a 12-h
vernight fast. Diabetes was defined as a fasting glucose
7.0 mmol/l and/or a history of diabetes and taking oral
ypoglycemic agents or insulin. Hypertension was defined
s a systolic BP 140 mm Hg, and/or a diastolic BP 90
m Hg, and/or a history of hypertension or taking antihy-
ertensive drugs. Dyslipidemia was defined as a TCHOL
5.18 mmol/l and/or triglycerides 1.70 mmol/l and/or
DL-C 1.04 mmol/l in men, and 1.30 mmol/l in
omen and/or a history of dyslipidemia and taking antidys- cipidemia drugs. The history of
iabetes, hypertension, or dyslip-
demia was collected by patient
elf-reported questionnaire. For
xample, patients who reported
hysician-diagnosed diabetes and
ook antidiabetes medication were
lassified as “history of diabetes.”
he study complies with the
eclaration of Helsinki in that
thic committee approval for pa-
ient recruitment and data anal-
ses was obtained from the MJ
esearch Foundation Review
ommittee in Taiwan.
uestionnaire. Cigarette smoking,
lcohol consumption, betel nut
hewing, and physical activity
istories were recorded for each
ubject from a questionnaire.
urrent, former, or never users
ere defined as those subjects
ho reported current use, any prior use, or never use of betel
uts, respectively, in the baseline survey. Physical activity
as divided into 3 levels: none-to-mild (exercise 1 h per
eek); moderate (exercise 1 to 4 h per week); and vigorous
exercise 5 h per week). Income was divided into 3 levels:
ow ($12,500 [USD]/year); middle ($12,500 to $37,500/
ear); and high ($37,500/year). Education was also di-
ided into 3 levels: low (elementary school and below);
iddle (junior and senior high school); and high (college/
niversity and above). All participants (n  115,746) have
omplete data for age, sex, BMI, total T4, TSH, BP, fasting
lucose, lipid profile, disease status, mortality status, and
urvival time. Although some lifestyle and socioeconomic
actors were missing, 83.3% of participants (n  96,383)
ad all covariates measured.
tatistical analysis. The data were presented as the mean
nd standard deviation for continuous variables. The Stu-
ent t test for unpaired data was used for the comparison of
ean values between 2 groups. Proportions and categorical
ariables were tested by the chi-square test. The character-
stics of subjects with SCH or euthyroidism are shown in
able 1. Cox proportional hazards regression analyses ad-
usted for potential confounders were used to estimate the
elative risks (RRs) for death from all causes and from
VD. We adjusted the covariates according to the tradi-
ional CVD risk factors or nontraditional risk factors, or on
he basis of their relationship with either SCH (predictor)
r death (outcome) in univariate analysis (p  0.05). For
xample, age and sex are strongly associated with mortality,
o we adjusted these 2 covariates in our Cox proportional
azards regression analyses (model 1). Lifestyle and socio-
conomic status such as smoking, alcohol drinking, physical
ctivity, income level, and education level are traditional
Abbreviations
and Acronyms
BMI  body mass index
BP  blood pressure
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
IHD  ischemic heart
disease
RR  relative risk
SCH  subclinical
hypothyroidism
T4  thyroxine
TCHOL  total cholesterol
TSH  thyroid-stimulating
hormoneardiovascular risk factors for mortality, so we adjusted these
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betel nut chewing is associated with increased risk of CVD
and all-cause mortality in Taiwan, so we also adjusted this
covariate in model 2 (17). Hypertension, diabetes, and
dyslipidemia are chronic diseases associated with increased
CVD and all-cause mortality, so we further adjusted these
covariates in model 3. Participants with missing covariate
data were excluded in the Cox proportional hazards regres-
sion analyses. Among these models, there was no interac-
tion (p 0.05) between SCH and other variables, including
sex, age (65 or 65 years), or prevalent CVD diseases for
predicting the risk of all-cause and CVD mortality. The
unadjusted Kaplan-Meier survival curves of all-cause and
CVD for SCH and euthyroid subjects are shown in
Figures 1A and 1B. Competing risk approached by cumu-
lative incidence competing risk estimate were done in Table 2.
Stratified analysis by age and TSH level at entry for the
association between SCH and risk of all-cause and CVD
mortality is summarized in Table 3. All analyses were
performed with the SAS statistical package for Windows
(version 9.1, SAS, Cary, North Carolina).
Results
There were 3,669 deaths during the 10 years of follow-up;
680 deaths were due to CVD. At the baseline survey, there
were 1,841 (1.6%) subjects with SCH and 113,905 (98.4%)
subjects with euthyroidism. As shown in Table 1, subjects
with SCH were older and had higher BMIs, BP, and fasting
glucose, TCHOL, HDL-C, and triglycerides levels than
subjects with euthyroidism. SCH subjects also differed from
euthyroid subjects with respect to smoking, alcohol con-
sumption, betel nut chewing, income, and education.
Participants who died during the follow-up period were
older, more frequently male, and had higher BMIs, BP, and
fasting glucose, TCHOL, and triglycerides levels, and lower
HDL-C levels than survivors (data not shown). The prev-
alence of smoking, alcohol consumption, betel nut chewing,
low income, and low education was less in survivors (data
not shown). To analyze the association between SCH and
mortality, we adjusted those factors to avoid possible con-
founding.
Using Cox proportional hazards regression analyses with
adjustment for potential confounders and competing risk
approach by cumulative incidence competing risk estimate,
the RRs for all-cause mortality and CVD deaths were
higher among subjects with SCH than among subjects with
euthyroidism (Table 2). However, the proportional hazards
assumption was not held (p  0.05). The Kaplan-Meier
survival curves revealed a more significant difference in
survival between SCH and euthyroid subjects after 5 years
(Figs. 1A and 1B). Therefore, we added 1 interaction term
of survival time and SCH status in the Cox proportional
hazard model, and survival time was categorized into 5
years and 5 years. The actual number of deaths and CVD
deaths in the 2 groups, before and after 5 years follow-up,were 1,565 and 2,104 for all-cause death and 306 and 374
for CVD deaths, respectively. Compared with euthyroid
subjects, the adjusted RRs (95% confidence interval [CI])
for all-cause mortality among 5 years, 5 years, and
overall survival time were 1.08 (0.71 to 1.64), 1.53 (1.13 to
2.06), and 1.30 (1.02 to 1.66) in subjects with SCH,
respectively (model 3 in Table 2). The adjusted RRs (95%
CI) for CVD deaths among 5 years, 5 years, and overall
survival time were 1.40 (0.64 to 3.05), 1.76 (0.90 to 3.41),
and 1.68 (1.02 to 2.76) in subjects with SCH, respectively
Figure 1 Kaplan-Meier Survival Curves for Subjects
With SCH Versus Subjects With Euthyroidism
(A) All-cause mortality and (B) cardiovascular disease (CVD)-related mortality.
The all-cause and CVD mortality are significantly different (the log-rank test
p  0.001) between both subject groups. SCH  subclinical hypothyroidism.(model 3 in Table 2).
ty lipop
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August 21, 2012:730–7 Subclinical Hypothyroidism and MortalityAlthough there was no interaction (p  0.05) between
SCH and age, we found that SCH increased the risks of
all-cause and CVD mortality in older subjects (Table 3).
The risks categorized by different TSH levels at entry are
also shown in the table.
Discussion
Factors influencing the prevalence of SCH include TSH
cutoff to define SCH, the race, sex, and age distribution of
the population, pre-existing presence of autoimmune thy-
roid disorders, and iodine intake (5). The prevalence of
Baseline Characteristics According to Status ofTable 1 Baseline Characteristics According
Subclinica
(n
Age, yrs 47
Male 51
Height, cm 159
Body weight, kg 59
BMI, kg/m2 23
Systolic BP, mm Hg 124
Diastolic BP, mm Hg 74
Fasting glucose, mmol/l 5.6
TCHOL, mmol/l 5.3
Triglycerides, mmol/l 1.5
HDL-C, mmol/l 1.2
TSH, mIU/l 7.0
T4, nmol/l 93
Diabetes 12
Hypertension 51
Smoking (n  110,386)
Never 1,41
Former 10
Current 23
Alcohol consumption (n  106,136)
Never 1,36
Former 6
Current 22
Betel nut chewing (n  109,332)
Never 1,61
Former 4
Current 6
Physical activity (n  109,003)
None/mild 87
Moderate 57
Vigorous 27
Income (n  108,593)
Low 1,03
Middle 56
High 7
Education (n  112,286)
Low 63
Middle 64
High 49
The Student t test was used for comparing mean values of contin
transformation was used for normal distribution. The Pearson chi-squ
BMI  body mass index; BP  blood pressure; HDL-C  high-densi
cholesterol; TSH  thyroid-stimulating hormone.SCH in this study was approximately 1.6%, which is lowerthan in other countries (1–3,23,24). In a community of
Southern Taiwan, the prevalence of SCH in the elderly was
reported to be 1.5% in women and 1.7% in men (25). The
prevalence of SCH in our cohort was compatible with that
study. In general, prevalence of SCH increased with age and
was higher in women (1,3). As in those reports, our SCH
subjects were older and more likely to be women than were
euthyroid subjects. Taiwan used to be an area of iodine
deficiency. The prevalence of endemic goiter was reduced
markedly after an island-wide salt iodination campaign
starting in 1967 (26). Lacking thyroid autoantibody data,
and Euthyroidismtatus of SCH and Euthyroidism
thyroidism
1)
Euthyroidism
(n  113,905) p Value
4.1 42.9 13.9 0.001
.8%) 54,471 (47.8%) 0.001
.9 162.2 8.5 0.001
1.2 61.0 11.5 0.001
.7 23.1 3.5 0.001
3.0 120.4 20.6 0.001
2.8 73.4 12.7 0.001
.62 5.48 1.29 0.001
.04 5.21 1.00 0.001
.13 1.41 1.19 0.001
.41 1.26 0.40 0.001
.44 1.56 0.79 0.001
7.3 99.9 19.1 0.001
%) 5,430 (4.8%) 0.001
.0%) 22,728 (20.0%) 0.001
0.001
.1%) 77,045 (70.9%)
%) 7,148 (6.6%)
.2%) 24,452 (22.5%)
0.001
.7%) 82,023 (78.5%)
%) 3,612 (3.5%)
.7%) 18,856 (18.0%)
0.001
.8%) 96,312 (89.5%)
%) 5,380 (5.0%)
%) 5,918 (5.5%)
0.252
.7%) 53,639 (50.0%)
.5%) 37,828 (35.3%)
.8%) 15,816 (14.7%)
0.001
.6%) 51,278 (48.0%)
.8%) 48,833 (45.7%)
%) 6,803 (6.4%)
0.001
.7%) 25,355 (22.9%)
.3%) 40,270 (36.4%)
.5%) 44,885 (40.7%)
ariables between groups; data are shown as the mean  SD; log
t was used for categorical data; and data are shown as n (%).
rotein cholesterol; SCH  subclinical hypothyroidism; TCHOL  totalSCHto S
l Hypo
 1,84
.1 1
2 (27
.2 7
.6 1
.5 3
.2 2
.7 1
2 1
6 1
4 1
9 0
7 2
.1 1
2 (6.6
6 (28
1 (81
0 (5.7
0 (13
0 (82
0 (3.6
5 (13
5 (93
4 (2.6
3 (3.7
2 (50
7 (33
1 (15
5 (61
8 (33
6 (4.5
4 (35
5 (36
7 (28
uous v
are testhe status of thyroid autoimmunity in our population is
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Subclinical Hypothyroidism and Mortality August 21, 2012:730–7unclear. The cause of the low prevalence of SCH in
Taiwanese remains to be investigated.
It has been reported that serum TSH concentrations are
positively associated with increasing BMI (27,28). How-
ever, some of the literature has reported no difference in
BMI between SCH and euthyroid subjects (11,13,29,30).
Imaizumi et al. (24) noted the correlation of SCH and
higher BMI in women but not in men. Our data revealed
that subjects with SCH had higher BMI than euthyroid
subjects.
The Colorado study revealed an increasing trend of
TCHOL, triglyceride, and low-density lipoprotein choles-
terol levels as thyroid function declined (2). Some studies
reported that TCHOL and low-density lipoprotein choles-
terol levels were positively correlated with serum TSH
(31,32). Compared with euthyroid subjects, male SCH
subjects may have higher TCHOL levels (11,29), higher
triglyceride levels (11), or higher HDL-C levels (30). As in
previous studies, our data revealed that patients with SCH
had increased TCHOL, triglycerides, and HDL-C levels
compared with euthyroid subjects.
The putative associations between SCH and hyperten-
sion are not well established. Certain studies reported
higher systolic BP, diastolic BP, or prevalence of hyperten-
sion in SCH subjects (11,33,34), whereas others demonstrated
no association of SCH and hypertension (13,24,29,30,35). Duan
et al. (23) reported SCH as an independent predictor of
increased SBP and pulse pressure in females. In this
study, subjects with SCH had a higher systolic BP,
diastolic BP, and prevalence of hypertension than euthy-
roid subjects.
Previous studies revealed that the level of fasting glucose
RR (95% CI) of SCH for All-Cause andCVD Mortality in Several Different ModelsTable 2 RR (95% CI) of SCH for All-Cause andCVD Mortality in Several Different Models
Mortality
All-Cause CVD
Model 1
Survival 5 yrs 1.19 (0.84–1.70) 1.67 (0.78–3.57)
Survival 5 yrs 1.38 (1.05–1.80)* 1.69 (0.87–3.29)
Overall 1.24 (1.00–1.53)* 1.66 (1.01–2.73)*
Model 2
Survival 5 yrs 1.07 (0.70–1.62) 1.36 (0.63–2.96)
Survival 5 yrs 1.51 (1.12–2.04)† 1.73 (0.89–3.36)
Overall 1.29 (1.02–1.65)* 1.66 (1.01–2.73)*
Model 3
Survival 5 yrs 1.08 (0.71–1.64) 1.40 (0.64–3.05)
Survival 5 yrs 1.53 (1.13–2.06)† 1.76 (0.90–3.41)
Overall 1.30 (1.02–1.66)* 1.68 (1.02–2.76)*
CVDmortality was determined with a competing risk approach by cumulative incidence competing
risk estimate with adjustment for non-CVD mortality. The models used Cox proportional hazards
regression analyses adjusted for potential confounders: model 1 adjusted for age and sex; model
2 included the confounders in model 1 plus BMI, smoking, alcohol consumption, betel nut chewing,
physical activity status, income, and education level; and model 3 included the confounders in
model 2 plus diabetes, hypertension, and dyslipidemia. *p  0.05; †p  0.01.
CI  confidence interval; CVD  cardiovascular disease; RR  relative risk; other abbreviations
s in Table 1.(29,30) and hemoglobin A1C (30), or prevalence of diabetesmellitus (11,13,24) did not differ between the SCH and
euthyroid subjects. In contrast to those reports, our study
found higher fasting glucose and higher prevalence of
diabetes in SCH versus euthyroid subjects.
The cardiovascular system is a specific target of thyroid
hormone. As a novel vasodilator, triiodothyronine (T3)
directly affects the vascular smooth muscle cells that pro-
mote relaxation (5,36). Being associated with hypercholes-
terolemia, impaired cardiac contractility and diastolic func-
tion, increased systemic vascular resistance, decreased
endothelial-derived endothelial factors, and increased
C-reactive protein and homocysteine levels, SCH will
theoretically increase cardiovascular risk (4–6,37). How-
ever, studies concerning the association between SCH and
CVD have disparate results (11–16,24,38–44). SCH has
been associated with increased prevalence of coronary heart
disease (CHD) (11,38–40) or incident ischemic heart
disease (IHD) (41). Imaizumi et al. (24) reported that SCH
was associated with IHD in men but not in women. Hak et
al. (42) reported SCH as a strong indicator of risk for
atherosclerosis and myocardial infarction in elderly women.
By contrast, several studies reported no association between
SCH and CHD (13,43), IHD (44), or CVD (13,24).
Rodondi et al. (12) reported that SCH is associated with
an increased risk of congestive heart failure among older
adults with a TSH level of 7.0 mIU/l, but not with other
cardiovascular events. Factors such as TSH cutoff, CVD
definition, characteristics of study subjects, severity of
SCH, and T4 regimen may confound the study results.
The associations of SCH with all-cause or CVD mortal-
ity were controversial in previous studies. Several studies
reported no association of SCH with death from CVD
(11–13), IHD (44), or all-cause mortality (12,13,44). In the
Whickham Survey, SCH was associated with IHD-related
mortality over the 20 years of follow-up (41). In a cohort of
atomic bomb survivors from Nagasaki, increased mortality
from all causes in years 3 to 6 were apparent in men with
RR (95% CI) of SCH for All-Cause and CVDMortality Stratified by Age and by TSH Levels at EntryTable 3 RR (95% CI) of S H for All-Cause and CVDMortality Stratified by Age and by TSH Levels at Entry
Mortality
All-Cause CVD
Age, yrs
65 (n  105,948) 1.08 (0.75–1.56) 1.22 (0.50–2.98)
65 (n  9,798) 1.53 (1.11–2.11)* 2.02 (1.10–3.70)*
p value for interaction 0.093 0.276
TSH, mIU/l
0.47–4.99 (n  113,905) 1.00 (Reference) 1.00 (Reference)
5–9.99 (n  1,635) 1.38 (1.08–1.78)* 1.80 (1.07–3.01)*
10–19.96 (n  206) 0.68 (0.26–1.81) 0.91 (0.13–6.44)
p value for trend 0.107 0.080
Age was stratified as 65 and 65 years, and TSH levels were stratified as 5 to 9.99 and 10 to
19.96 mIU/l using Cox proportional hazards regression analyses adjusted for age, sex, BMI,
diabetes, hypertension, dyslipidemia, smoking, alcohol consumption, betel nut chewing, physical
activity status, income, and education level. The reference group consisted of participants with
euthyroidism. *p  0.05.
Abbreviations as in Tables 1 and 2.
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status had been reported to be associated with an increased
risk of mortality in patients with cardiac disease (45).
Haentjens et al. (46) reported an increased RR of all-cause
mortality in SCH patients with comorbid conditions. The
Leiden 85-Plus Study observed that elderly subjects with
increasing levels of TSH had lower mortality rates (47).
Recent meta-analysis studies concerning the association
between SCH and mortality had varied conclusions. Völzke
et al. (14) concluded that the current evidence for the
association of SCH with mortality is weak. Ochs et al. (15)
reported a modest increased risk for CHD and mortality in
SCH. Rodondi et al. (16) concluded that SCH is associated
with an increased risk of CHD events and CHD mortality
in those with higher TSH levels, but not all-cause mortality.
Our study revealed a significant association between SCH
and all-cause and CVD mortality in subjects with TSH
levels that ranged from 5 to 9.9 mIU/l. With relatively small
numbers, the results became unstable in subjects with higher
TSH. Razvi et al. (48) reported that SCH increased IHD
events and cardiovascular mortality only in younger subjects.
Rodondi et al. (16) reported that SCH significantly in-
creased CHD mortality and total mortality in subjects age
65 to 79 years, but not in other age groups. Our data
revealed that SCH was associated with increased risk for
all-cause and CVD mortality, especially in older subjects.
Some reports suggested that treating SCH by T4 replace-
ment may reduce symptoms of hypothyroidism, prevent
progression to overt hypothyroidism, improve quality of life,
and potentially decrease CVD events and mortality (4–6).
However, this remains to be proven in randomized con-
trolled studies. In the Whickham Survey, treatment of SCH
with levothyroxine attenuated IHD-related morbidity and
mortality (41). Cooper et al. (49,50) reported significant
improvement in symptoms of hypothyroidism and sug-
gested a therapeutic trial for SCH patients with symptoms
consistent with mild hypothyroidism, hypercholesterolemia,
or a goiter. On the other hand, Kong et al. (51) did not find
any significant improvement in their patients with mild
SCH. Conflicting results in studies could be caused by the
differing nature and number of patients recruited, study
design, dose of T4 therapy, and small sample size. In their
review, Surks et al. (8) concluded that data addressing
associations of subclinical thyroid disease with symptoms or
adverse clinical outcomes or benefits of treatment were
insufficient or absent. In the United States, a consensus
statement of 3 societies recommended against routine treat-
ment of SCH patients with serum TSH levels of 4.5 to 10
mIU/l, but recommended treatment for patients with TSH
levels 10 mIU/l (7).
Study limitations. Although we have demonstrated that
SCH is associated with an increased risk for all-cause and
CVD mortality, there are several limitations in our study.
First, measurement of serum total T4 could be influenced by
nonthyroidal conditions, such as alteration in thyroxine-
binding globulin or the use of oral contraceptives. We didnot measure free T4 levels in our patients. Some may argue
that measuring total T4, not free T4, could lead to misclas-
sification of thyroid function status. However, thyroid
function tests that measured both serum TSH level and
total T4 level were also used in previous reports (16).
Second, SCH is most often caused by chronic lymphocytic
thyroiditis (5). The presence or absence of thyroid autoan-
tibodies may influence the progression of SCH to overt
hypothyroidism (6). We did not have data on thyroid
autoantibodies or thyroid sonography. The prevalence of
autoimmune thyroid disorders in our participants was not
clear. Third, conditions such as subacute, painless, postpar-
tum thyroiditis or withdrawal of thyroid hormone therapy in
euthyroid patients may cause transient SCH (5). In our
study, the serum TSH and T4 levels and other laboratory
data were checked when subjects were recruited. We did not
have follow-up thyroid function data to confirm the persis-
tence of SCH. The changes of other covariates during the
follow-up period were also not clear. Fourth, the T4
regimen in SCH patients may affect the mortality. We did
not know whether or not the patients with SCH were
treated by T4 during the follow-up period. However, it is a
common limitation in these types of analyses (11–13,24).
Spontaneous normalization of SCH and T4 regimen for
SCH may bias the association between SCH and mortality
toward the null. Our study demonstrated a positive associ-
ation between SCH and mortality; lack of follow-up thyroid
function data or medication history does not jeopardize the
value of our observation. Fifth, deaths were ascertained by
computer linkage to the national death registry using ID
numbers. Possible inherent limitations of using ICD-9
codes may exist, but have been minimized as in our previous
studies (17,18). Sixth, some participants had missing data in
lifestyle and socioeconomic variables. The missing rate was
16.7%, indicating that potential selection bias might exist.
There exists a slight difference in distributions of age, sex,
and SCH status between individuals with and without
missing data. This kind of missing error might be random as
long as there is a nondifferential relationship in age, sex, and
SCH status with all-cause and CVD mortality. Thus, the
biased results in the effect may be toward the null, a lesser
threat to validity. Seventh, this study is observational in
nature. Even with adjustment for age, sex, traditional CVD
risk factors, and nontraditional risk factors, as in our
analysis, the possibility of residual confounding remained.
Conclusions
We have found that old age and female sex increase the
prevalence of SCH. Patients with SCH had higher BMIs
and increased frequency of hyperlipidemia, diabetes, and
hypertension compared with euthyroid subjects. Further-
more, SCH is independently associated with an increased
risk for all-cause and CVD mortality after adjusting for
the aforementioned confounders. Adult Taiwanese with
736 Tseng et al. JACC Vol. 60, No. 8, 2012
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cular mortality.
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